Supplied formLipidated peptide (39-mer, linear, C20 fatty-diacid-acylated via γGlu-(AEEA)2 linker on the Lys20 side chain)
Lead time10–18 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
Research value includes dual-receptor pharmacology, biased-signaling and structure-activity comparisons, analytical qualification of lipidated peptides, formulation and stability studies, and controlled comparison with single-receptor or other multi-agonist standards
These are not claims of weight loss, glycemic control or OSA treatment for this product.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
2023788-19-2
Formula
C225H348N48O68
Molecular weight
4813.5 g/mol
Appearance
Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA
Purity
≥ 99.0% · target, verify batch COA
Storage
Follow the released-batch storage statement and SDS. Confirm post-opening or prepared-sample stability against the laboratory's validated protocol.
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about Tirzepatide
Tirzepatide is a 39-residue synthetic peptide with two Aib residues, a C-terminal amide and a C20 fatty-diacid albumin-binding moiety attached through a gamma-Glu-(AEEA)2-containing linker. It activates GIP and GLP-1 receptors. FDA-approved Mounjaro is a finished formulation for type 2 diabetes, while Zepbound has finished-product indications for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Those approvals and their clinical evidence do not apply to this RUO analytical lot.
Dual GIPR/GLP-1R signaling; receptor-bias and structure-activity studies; lipidated-peptide identity and impurity methods; albumin-binding, formulation and stability research; controlled comparison with semaglutide, dulaglutide or multi-agonist reference standards.
Mechanism context
The question the literature is testing
Tirzepatide engages GIPR and GLP-1R with receptor- and assay-dependent signaling profiles. Albumin association from its lipidated side chain contributes to prolonged exposure in approved formulations. Cellular signaling, animal models and clinical outcomes should be reported at their own evidence levels.
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
Research Use Only; not a sterile finished drug and not for human or veterinary use
FDA boxed warnings, contraindications and adverse reactions describe approved Mounjaro or Zepbound formulations and should be consulted in their current labels, not rewritten as instructions for this lot
Handle under the SDS and institutional risk assessment.
Interactions reported in the literature
For bench studies, control albumin or serum content, receptor expression, glucose, assay timing and comparator concentration
No clinical combination with insulin, metformin, GLP-1 agonists, GH-axis peptides or other research compounds is recommended.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
Tirzepatide batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
2 mg
5 mg
10 mg
15 mg
20 mg
30 mg
40 mg
50 mg
60 mg
80 mg
90 mg
100 mg
120 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Ask for the current packet, not a generic certificate
Require full modified sequence, lipidation site and linker identity, RP-HPLC purity with method, intact mass, LC-MS/MS sequence/modification evidence, peptide content, related substances, counterion, water and residual solvents
Endotoxin, bioburden and sterility are separate lot tests
Appearance and solution clarity cannot prove identity or suitability.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
TR22 mg10 vials
TR55 mg10 vials
TR1010 mg10 vials
TR1515 mg10 vials
TR2020 mg10 vials
TR3030 mg10 vials
TR4040 mg10 vials
TR5050 mg10 vials
TR6060 mg10 vials
TR7575 mg10 vials
TR8080 mg10 vials
TR9090 mg10 vials
TR100100 mg10 vials
TR120120 mg10 vials
Other format
Also available as a nasal spray (US stock)
10 mL nasal spray bottle
Besides lyophilized vials, Tirzepatide is also supplied as a nasal spray solution, shipped from our US stock.
Follow the released-batch storage statement and SDS. Confirm post-opening or prepared-sample stability against the laboratory's validated protocol.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
Identity: PubChem CID 156588324. Regulatory context: current FDA/Drugs@FDA Mounjaro and Zepbound labels. Clinical evidence context: linked SURPASS and SURMOUNT primary studies. Cardiovascular outcomes: PMID 41406444, which established noninferiority but not superiority versus dulaglutide.
01
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine · 2022 · peer-reviewed original research (phase 3 randomized controlled trial)
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
The Lancet · 2023 · peer-reviewed original research (phase 3 randomized controlled trial)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
The Lancet · 2021 · peer-reviewed original research (phase 3 randomized controlled trial)
What are Tirzepatide's reference identity values (CAS, formula, MW)?+
Tirzepatide is associated with CAS 2023788-19-2 and PubChem CID 156588324. The neutral reference structure has formula C₂₂₅H₃₄₈N₄₈O₆₈ and average mass of approximately 4813 g/mol. It is a 39-residue synthetic peptide carrying a C20 fatty-diacid moiety through a linker on a lysine side chain. The released-lot COA must identify the exact form, counterion, water basis, theoretical mass, observed mass and quantitative peptide content; catalogue values cannot substitute for batch evidence.
How is Tirzepatide identity confirmed for a metabolic-research workflow?+
Ask sales for the matching batch COA first; it states the identity and purity work actually completed. If the buyer's written procedure requires high-resolution mass, LC-MS/MS or peptide mapping, related-substance profiling, quantitative content, counterion, water, residual solvents or raw data beyond that record, agree the method, acceptance criteria, reporting, timing and cost before quotation.
How does Tirzepatide differ from Semaglutide in chemistry and receptor pharmacology?+
Semaglutide is a 31-residue, C18-lipidated selective GLP-1R agonist, whereas tirzepatide is a 39-residue, C20-lipidated dual GIPR/GLP-1R agonist with a different sequence, linker and receptor-signaling profile. Outcomes from approved formulations or clinical trials cannot be reduced to a universal class effect at ‘comparable exposure’ or transferred to an RUO lot. Comparative experiments should match molar concentration, albumin or serum conditions, receptor expression, assay timing and formulation.
